Zusammenfassung
Das Bronchuskarzinom ist in der Krebsinzidenz mit 22% nach wie vor die häufigste bösartige Neubildung des Mannes, jedoch ist auch bei Frauen ein beträchtlicher Anstieg in der Häufigkeit der Neuerkrankungen festzustellen — 1981 waren in den U.S.A. 8% aller Neoplasien bei Frauen Bronchuskarzinome (1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Silverberg, E: Cancer Statistics. American Cancer Society. 1981.
Carter, S. K., et al: Chemotherapy of cancer, S. 193–199. New York- London-Sydney-Toronto: Wiley Medical Publication. 1977.
Katlic, M., Carter, D: Prognostic implication of histology, size and location of primary tumors. In: Lung Cancer: Progress in Therapeutic Research (Muggia, F., Rozencweig, M., Hrsg.), S. 143–150. New York: Raven Press. 1979.
Kreyberg, L: Histologie typing of lung tumours. Geneva: World Health Organization. 1967.
Monfardini, S., et al: Manual of cancer chemotherapy, 3. Aufl., S. 123–127. Geneva: UICC. 1981.
Nissen, I., et al: Clinical trial of VP16–213 i.v. twice weekly in advanced neoplastic disease. Cancer 45, 232–235 (1980).
Itri, L., et al: Phase II trial of VP 16-213 in non-small cell lung cancer (NSCLC). Cancer Clinical Trials 1981.
Falkson, G., et al: A clinical trial of the oral form of 4’-demethylepipodo- phyllotoxin-ß-D-ethylidene glucoside. Cancer 35, 1141–1144 (1975).
Eagan, R., et al: VP 16-213 chemotherapy for advanced squamous cell and adenocarcinoma of the lung. Cancer Treat. Rep. 62, 843–844 (1978).
Cavalli, F., et al: A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141540) in the treatment of bronchogenic carcinoma. Tumori 63, 169–173 (1977).
Eagan, R., et al: Cyclophosphamide and VP16 with or without cisplatinum in squamous cell and small cell lung cancer. Cancer Treat. Rep. 65, 453–458 (1981).
Morasca, L., et al: VP 16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. First Internat. Symposium on the Podophylloto- xins in Cancer Therapy. Southampton, England, 8. und 9. Juli 1981.
Schilcher, R. B., et al: Ifosfamide and VP 16-213 combination chemotherapy in inoperable bronchogenic carcinoma. Abstracts of the Fifth Annual Meeting of the Medical Oncology Society, Nice, France, 1. bis 3. Dezember 1979, S. 43. Berlin-Heidelberg-New York: Springer. 1979.
Mabel, J. A., et al: Therapeutic synergism in murine tumours for combi- nations of cisplatinum with VP 16-213 or BCNU. Proc. AACR and ASCO 20, 230 (1979).
Dhingra, H. M., et al: Phase II clinical study of cis-dichlorodiamminepla- tinum (CCDP) and VP 16-213 (VP16) in combination for patients (PTS) with extensive non-small cell lung cancer (E-NSCLC). Proc. AACR and ASCO 22, 200 (1981).
Mitrou, P. S., et al: Behandlungsergebnisse mit VP 16-213 und Cisplatinum bei inoperablen nichtkleinzelligen Bronchuskarzinomen. Etopo- sid-Symposium, Frankfurt/Main, Mai 1981.
Cavalli, F., Joss, R: Cisplatinum and etoposide (DDP/VP 16-213) in the treatment of non-small cell lung cancer. Proceedings International Symposium, New Drugs for Cancer Therapy in the Eighties, Rome 1981.
Klastersky, J., et al: Therapy with cisplatinum and etoposide in bronchogenic squamous cell cancer and adenocarcinoma. Proceedings of International Symposium, New Drugs for Cancer Therapy in the Eighties, Rome 1981.
Gralla, R. J., et al: Cisplatinum and Vindesine combination chemotherapy for advanced Carcinoma of the lung: A randomized trial investi- gating two dosage schedules. Ann. Int. Med. 95, 414–420 (1981).
Hyde, L., et al: Cell type and the natural history of lung cancer. JAMA 193, 140–142 (1965).
Brunner, K. W., et al: Comparison of the biologic activity of VP 16-213 given i.v. and orally in capsules or drink ampules. Cancer Treat. Rep. 60, 1377–1379 (1976).
Klastersky, J., et al: Cisplatinum, ADM and etoposide (CAV) for remission induction of small-cell bronchogenic Carcinoma: evaluation of efficacy and toxicity and pilot study of a “late intensification” with autologous bone-marrow rescue. Cancer 50 (4), 652–658 (1982).
Aisner, J., et al: Doxorubicin, cyclophosphamide and VP 16-213 (ACE) in the treatment of small cell lung cancer. Cancer Chemother. Pharmacol. 7 (2/3), 187–193 (1982).
Aisner, J., et al: Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat. Rep. 66 (2), 221–230 (1982).
Abeloff, M. D., et al: Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. Cancer Treat. Rep. 65 (7–8), 639–646 (1981).
Aroney, R. S., et al: Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung. Cancer 49 (12), 2449–2454 (1982).
Sierocki, J. S., et al: Cis-dichlorodiammineplatinum (II) and VP 16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat. Rep. 63, 1593–1597 (1979).
Linninger, T. R., et al: Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer 48, 2147–2153 (1981).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag/Wien
About this chapter
Cite this chapter
Hausmaninger, H. (1984). Etoposid in der Behandlung des inoperablen Bronchuskarzinoms. In: Schwarzmeier, J., Deutsch, E., Karrer, K. (eds) Etoposid (VP 16-213) in der Therapie maligner Erkrankungen. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8755-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8755-5_11
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-81801-5
Online ISBN: 978-3-7091-8755-5
eBook Packages: Springer Book Archive